Chronic Lymphocytic Leukemia (CLL) Treatments

Find Chronic Lymphocytic Leukemia (CLL) Treatments

Brand Name

Fludarabine

View Brand Information
FDA approval date: November 16, 2007
Classification: Nucleoside Metabolic Inhibitor
Form: Injection

What is Fludarabine?

Fludarabine Phosphate Injection is a nucleotide metabolic inhibitor indicated for: The treatment of adult patients with B-cell chronic lymphocytic leukemia who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. Benefit in treatment-naïve or non-refractory CLL patients is not established.

Approved To Treat

Top Global Experts

View All
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Enrollment Status: Recruiting
Publish Date: April 16, 2026
Intervention Type: Biological
Study Phase: Phase 2/Phase 3

Summary: RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies
A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies
Enrollment Status: Recruiting
Publish Date: April 16, 2026
Intervention Type: Drug, Biological, Device
Study Phase: Phase 1

Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the cancer cells to create substances called neoepitopes. Researchers want to test a method of treating blood cancers by altering a person s T cells (a type of immune cell) to target neoepitopes.

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: April 16, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: Phase 1 is to find the recommended dose of KSQ-004EX to give to participants with advanced solid tumors. Phase 2 is to learn if KSQ-004EX at the recommended dose found in Phase1 can help to control advanced solid tumors. The safety and effects of KSQ-004EX will also be studied in both phases.

View All Clinical Trials

Related Latest Advances

Clinical Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Very Early-Onset Inflammatory Bowel Disease Caused by IL-10RA Mutation
Clinical Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Very Early-Onset Inflammatory Bowel Disease Caused by IL-10RA Mutation
Journal: Zhongguo shi yan xue ye xue za zhi
Published: March 18, 2026
Prognostic impact of onset timing on response to methylprednisolone pulse therapy for idiopathic pneumonia syndrome after allogeneic hematopoietic cell transplantation.
Prognostic impact of onset timing on response to methylprednisolone pulse therapy for idiopathic pneumonia syndrome after allogeneic hematopoietic cell transplantation.
Journal: Pediatric hematology and oncology
Published: March 09, 2026
Cryoglobulinemia Type II: Sustained Remission After B-Cell-Directed Therapy.
Cryoglobulinemia Type II: Sustained Remission After B-Cell-Directed Therapy.
Journal: The American journal of case reports
Published: March 07, 2026
View All Latest Advances